- Home
- SCNX vs PASG Comparison
SCNX vs PASG Comparison
Compare SCNX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | PASG |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 28.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SCNX | PASG |
|---|---|---|
| Price | $0.42 | $8.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.50 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 350.7K | 28.3K |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.28 |
| 52 Week High | $3.61 | $20.00 |
Technical Indicators
Market Signals| Indicator | SCNX | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 38.07 |
| Support Level | $0.37 | $8.10 |
| Resistance Level | $0.60 | $8.85 |
| Average True Range (ATR) | 0.03 | 0.76 |
| MACD | 0.00 | 0.07 |
| Stochastic Oscillator | 27.40 | 5.42 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.